drugset / Trial / NCT01858116
PET Study of Breast Cancer Patients Using [68Ga]ABY-025
Phase 1/2
Completed
16 enrolled
Biomedical Radiation Sciences
Affibody · collabSwedish Cancer Society · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The study will evaluate \[68Ga\]ABY-025 for PET imaging of HER2 expression in subjects with HER2-positive or HER2-negative breast cancer.
Timeline
- Start
- 2013-04
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [68Ga]ABY-025 | Peptide | 100 ug | Intravenous |
| Subject | [68Ga]ABY-025 | Peptide | 500 ug | Intravenous |